Brought to you by 
Braeburn to market Titan Pharma’s Probuphine in North America; rights may be returned; terminated
14 Jan 2021
Executive Summary
Neurology company Titan Pharmaceuticals Inc. has licensed start-up Braeburn Pharmaceuticals SPRL exclusive US (including Puerto Rico) and Canadian rights to Probuphine (buprenorphine implant), which is awaiting approval for opioid addiction. The term of the transaction is 15 years, or when the last patent expires, whichever is later.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Braeburn to market Titan Pharma’s Probuphine in North America; rights may be returned; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice